Skip to main content
. 2018 Jan 9;41(4):731–738. doi: 10.2337/dc17-2233

Table 4.

Adjusted mean (SE) left ventricular structural and functional outcomes at year 25 according to the duration of prediabetes during follow-up (the CARDIA Study)

Duration of prediabetes (years)
Ptrend Per each additional 5 years
0 1–5 6–10 11–15 >15
Structural outcomes
 Left ventricular mass (g)
  No. of participants 1,273 619 527 223 175
  Model 1 178.9 (2.2) 181.9 (2.6) 188.9 (2.7) 189.5 (3.5) 189.9 (4.0) <0.001 3.8 (0.69)
  Model 2 168.0 (2.1) 166.5 (2.4) 170.9 (2.5) 168.2 (3.3) 166.8 (3.6) 0.54 0.39 (0.64)
 Relative wall thickness
  No. of participants 1,272 619 526 222 175
  Model 1 0.35 (0.004) 0.36 (0.004) 0.36 (0.004) 0.36 (0.006) 0.35 (0.006) 0.08 0.0019 (0.001)
  Model 2 0.35 (0.004) 0.35 (0.004) 0.36 (0.004) 0.36 (0.006) 0.35 (0.006) 0.53 0.0007 (0.001)
Systolic function outcomes
 Ejection fraction (%)
  No. of participants 1,273 619 527 223 175
  Model 1 68.6 (0.4) 69.9 (0.5) 70.0 (0.5) 69.8 (0.6) 68.4 (0.7) 0.10 0.20 (0.12)
  Model 2 68.8 (0.4) 70.1 (0.5) 70.2 (0.5) 70.0 (0.7) 68.6 (0.7) 0.13 0.20 (0.13)
 Longitudinal strain (%)
  No. of participants 1,224 611 519 229 173
  Model 1 −14.7 (0.1) −14.4 (0.1) −14.3 (0.1) −14.2 (0.2) −14.1 (0.2) <0.001 0.17 (0.04)
  Model 2 −14.9 (0.1) −14.6 (0.1) −14.6 (0.1) −14.5 (0.2) −14.5 (0.2) <0.001 0.13 (0.04)
Diastolic function outcomes
 e′ (cm/s)
  No. of participants 1,357 685 585 256 203
  Model 1 11.4 (0.1) 10.9 (0.1) 10.9 (0.2) 11.1 (0.2) 10.8 (0.2) <0.001 −0.20 (0.04)
  Model 2 11.6 (0.1) 11.2 (0.1) 11.2 (0.2) 11.5 (0.2) 11.3 (0.2) 0.002 −0.12 (0.04)
 E-to-e′ ratio
  No. of participants 1,345 681 584 253 202
  Model 1 7.5 (0.11) 7.8 (0.12) 7.8 (0.13) 7.6 (0.17) 8.0 (0.18) <0.001 0.12 (0.03)
  Model 2 7.3 (0.11) 7.5 (0.12) 7.4 (0.13) 7.2 (0.17) 7.4 (0.19) 0.20 0.04 (0.03)

Model 1 was adjusted for age, sex, race, educational attainment, study center, and duration of diabetes. Model 2 was adjusted for model 1 variables in addition to lifetime pack-years of smoking, use of blood pressure–lowering medication, and mean BMI, systolic blood pressure, and total cholesterol level during follow-up.